Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
5
63%
Ph phase_2
2
25%
Ph early_phase_1
1
13%

Phase Distribution

6

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Early Phase 1First-in-human
1(12.5%)
Phase 1Safety & dosage
5(62.5%)
Phase 2Efficacy & side effects
2(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(5)
Terminated(3)

Detailed Status

Completed5
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
71.4%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (12.5%)
Phase 15 (62.5%)
Phase 22 (25.0%)

Trials by Status

completed563%
withdrawn113%
terminated225%

Recent Activity

0 active trials
Showing 5 of 8
completedearly_phase_1

LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients

NCT04391595
completedphase_1

LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy

NCT04081259
completedphase_2

LY3214996 +/- HCQ in Pancreatic Cancer

NCT04386057
terminatedphase_1

Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

NCT04916236
terminatedphase_2

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

NCT04534283
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04391595Early Phase 1

LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients

Completed
NCT04081259Phase 1

LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy

Completed
NCT04386057Phase 2

LY3214996 +/- HCQ in Pancreatic Cancer

Completed
NCT04916236Phase 1

Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

Terminated
NCT04534283Phase 2

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Terminated
NCT02857270Phase 1

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Completed
NCT04043845Phase 1

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Withdrawn
NCT04033341Phase 1

A Study of LY3214996 in Healthy Participants

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8